期刊文献+

新疆地区汉族、维吾尔族帕金森病患者中血清免疫球蛋白、补体水平的临床研究 被引量:1

Clinical study on serum levels of immunoglobulins and complement of Han and Uygur patients with Parkinson's disease in Xinjiang region
下载PDF
导出
摘要 目的探讨新疆汉族、维吾尔族帕金森病(PD)患者血清中免疫球蛋白(IgG、IgA、IgM)及补体(C3、C4)水平是否具有差异。方法选择104例原发性帕金森病患者(PD组),其中汉族64例,维吾尔族40例;选择135例健康体检者为对照组,其中汉族84例,维吾尔族51例。采用特种蛋白分析仪检测血清中免疫球蛋白(IgG、IgA、IgM)及补体(C3、C4)的水平,分析汉族、维吾尔族PD患者的血清免疫球蛋白(IgG、IgA、IgM)、补体水平(C3、C4)是否存在差异及其与PD的关系。结果 PD组IgG值高于对照组(P<0.05)。维吾尔族PD组IgA值高于维吾尔族对照组(P<0.05)。汉族PD组与汉族对照组IgG、IgA、IgM、C3、C4值差异均无统计学意义(P>0.05),汉族PD与维族PD组各指标差异也无统计学意义(P>0.05)。将与总体PD相关的5个因素(IgG、IgA、IgM、C3、C4)进行Logistic回归分析提示,血清IgG每增加1个单位,PD的发生风险增加1.675倍(P=0.007,OR=1.675)。进一步将与汉族PD相关的5个因素(IgG、IgA、IgM、C3、C4)进行Logistic回归分析提示,血清IgG每增加1个单位,汉族PD的发生风险增加2.096倍(P=0.029,OR=2.096);但血清IgG水平与维族PD无关。结论 PD患者IgG值高于正常人;维吾尔族PD患者IgA值高于正常维吾尔族人;IgG可能是汉族PD的危险因素。 Objective To explore the difference of serum levels of immunoglobulin ( IgG, IgA,IgM) and complement ( C3, C4) in patientswith Parkinson' s disease(PD) between Han and Uygur nationality in Xinjiang province. Methods A total of 104 cases of primary Parkinson' s disease( PD group) were selected, including 64 cases of Han nationality and 40 cases of Uygur nationality. Another 135 healthy controls were selected as control group, including 84 cases of Han nationality and 51 cases of Uygur nationality. The serum lev- els of immunoglobulins (IgG, IgA, IgM) and complements (C3, CA ) were detected by special protein analyzer, and their relationship with PD were analyzed. Results IgG level in PD group was statistically higher than in control group( P 〈 0.05 ). The serum level of lgA in Uygur PD patients was higher than that in Uygur controls (P 〈 0.05 ). There was no significant difference in IgG, IgA, IgM, C3 and CA levels between Han PD group and Han control group ( P 〉 0.05 ) and between Han PD group and Uygur PD group ( P 〉 0.05 ). Lo- gistic regression analysis of the five factors associated with PD( IgG, IgA, IgM, C3, C4) showed that the risk of PD increased by 1. 675 times for each additional unit of IgG(P = 0. 007, OR = 1. 675 ). And the Logistic regression analysis showed that the risk of PD in- creased by 2. 096 times in Han nationality ( OR = 2. 096, P = 0. 029 ), however, the level of serum lgG was not associated with PD in Uygur nationality. Conclusion The lgG level is higher in PD patients than in normal controls. The IgA is higher in Uygur PD pa- tients than that of normal Uighurs. IgG may he a risk factor of PD in Han nationality.
出处 《山西医科大学学报》 CAS 2017年第2期156-160,共5页 Journal of Shanxi Medical University
基金 国家自然科学基金资助项目(U1503222)
关键词 帕金森病 IgG gA IGM C3 C4 Parkinson'sdisease IgG IgA IgM C3 C4
  • 相关文献

参考文献7

二级参考文献112

  • 1衣雪洁,常波,黄超群.运动、激素和免疫[J].体育科研,1997,18(4):32-35. 被引量:7
  • 2张达.运动员大负荷训练后免疫球蛋白动态变化[J].泉州师范学院学报,2004,22(4):102-105. 被引量:7
  • 3郝学志.胃癌患者的社会及家庭支持[J].中国全科医学,2004,7(20):1461-1462. 被引量:4
  • 4张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:617
  • 5Drouot X, Oshino S, Jarraya B, et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron, 2004, 44:769-778. 被引量:1
  • 6Benvenuti E, Cecchi F, Colombini A, et al. Extradural motor cortex stimulation as a method to treat advanced Parkinson's disease: new perspectives in geriatric medicine. Aging Clin Exp Res, 2006, 18:347-348. 被引量:1
  • 7Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA, 2002, 99:2344-2349. 被引量:1
  • 8Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128(Pt 12):2977-2986. 被引量:1
  • 9Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA, 2008, 105:5856-5861. 被引量:1
  • 10Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase Ⅰ trial. Lancet, 2007, 369:2097-2105. 被引量:1

共引文献1390

同被引文献7

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部